Article Sidebar
Published:
Jun 11, 2023DOI:
10.4314/tjpr.v22i2.9Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Physalin A alleviates inflammation and oxidative stress in mouse infantile pneumonia by inhibiting JAK/STAT3 and NF κB pathways
Abstract
Purpose: To investigate the effect of physalin A on infantile pneumonia in mice.
Methods: A mouse model of infantile pneumonia was established via intraperitoneal injection of lipopolysaccharide and verified using hematoxylin and eosin staining. Lipopolysaccharide-stimulated mice were then administered physalin A. The total protein content, number of cells, and levels of inflammatory-factor in bronchoalveolar lavage fluid (BALF) were determined. Inflammation and oxidative stress levels in lung tissues were determined by enzyme-linked immunosorbent assay (ELISA).
Results: Lipopolysaccharide injection induced shrinking of pulmonary alveoli in mice, but physalin A administration ameliorated the histopathologic damage in lung tissues and significantly reduced the total protein content and number of cells in the BALF of lipopolysaccharide-stimulated mice (p < 0.001). Moreover, physalin A also significantly down-regulated the levels of tumor necrosis factor-α, interleukin (IL)-6, IL-18, and IL-1β in BALF and lung tissues of lipopolysaccharide-treated mice (p < 0.001). Physalin A attenuated lipopolysaccharide-induced increases in malondialdehyde and myeloperoxidase as well as decreases in superoxide dismutase and glutathione in mouse lung tissues. Additionally, physalin A reduced the levels of p-JAK1, p-STAT3, and p-p65 in lung tissues of lipopolysaccharide-treated mice.
Conclusion: Physalin A exerts anti-inflammatory and anti-oxidant effect on lipopolysaccharide-induced lung injury in mice through the inactivation of JAK/STAT3 and NF-κB pathways. However, the effect of Physalin A on inflammation and oxidative stress in lipopolysaccharide-induced A549 cells will need to be investigated in further studies.
